| Ovarian Serous Cystadenocarcinoma studied in …STUDIED_INderived10 of 27show all (up to 200) |
|---|
| → studied in | NCT02101775Phase 2 · active not recruiting Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer · condition mapped ONTOLOGY_EXACT · 27 trials mapped (2 active) | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02142803Phase 1 · active not recruiting TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors · condition mapped ONTOLOGY_EXACT · 27 trials mapped (2 active) | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02122185Phase 2 · completed Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 27 trials mapped (2 active) | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02111941early Phase 1 · completed Vaccine Therapy for Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer · condition mapped ONTOLOGY_EXACT · 27 trials mapped (2 active) | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05074472Phase 1/Phase 2 · completed A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors · condition mapped ONTOLOGY_EXACT · 27 trials mapped (2 active) | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02283658Phase 2 · completed Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer · condition mapped ONTOLOGY_EXACT · 27 trials mapped (2 active) | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01074411Phase 1 · completed Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 27 trials mapped (2 active) | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00993616Phase 2 · completed Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin · condition mapped ONTOLOGY_EXACT · 27 trials mapped (2 active) | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00079430Phase 1 · completed Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer · condition mapped ONTOLOGY_EXACT · 27 trials mapped (2 active) | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00085358Phase 1 · completed Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer) · condition mapped ONTOLOGY_EXACT · 27 trials mapped (2 active) | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | clinicaltrials | graph → |